28 results on '"Juan Sierra Madero"'
Search Results
2. EFICÁCIA DURADOURA DE DOLUTEGRAVIR MAIS LAMIVUDINA NO TRATAMENTO ANTIRRETROVIRAL DE ADULTOS NAÏVE COM INFECÇÃO PELO HIV-1: RESULTADOS DE 144 SEMANAS DOS ESTUDOS GEMINI EM PARTICIPANTES DE CENTROS LATINO-AMERICANOS
- Author
-
Norma Porteiro, Pedro Cahn, Juan Sierra Madero, Choy Y. Man, Jörg Sievers, Rimgaile Urbaityte, Andrés Maldonado, Inez Prudente Martinez, and Jean van Wykd Jaime Andrade-villanueva
- Subjects
Infectious and parasitic diseases ,RC109-216 ,Microbiology ,QR1-502 - Abstract
Introdução: GEMINI-1/-2 demonstrou que dolutegravir (DTG) + lamivudina (3TC) foi não-inferior a DTG + tenofovir disoproxil fumarato/emtricitabina (TDF/FTC) em 48, 96 e 144 semanas em adultos virgens de tratamento. O objetivo desta análise foi examinar a eficácia e segurança de 144 semanas de DTG + 3TC vs DTG + TDF/FTC em participantes de centros latino-americanos incluídos nos estudos GEMINI-1/-2 (post hoc). Métodos: GEMINI-1/-2 são estudos de fase III idênticos, globais, duplo-cegos e multicêntricos; os participantes triados com RNA do HIV-1 ≤500.000 c/mL foram randomizados 1:1 (estratificados por RNA do HIV-1 e contagem de células CD4 +) para DTG + 3TC ou DTG + TDF/FTC, uma vez ao dia. O desfecho primário foi a proporção de participantes com RNA de HIV-1 plasmático
- Published
- 2022
- Full Text
- View/download PDF
3. EFICÁCIA DURADOURA DE DOLUTEGRAVIR (DTG) E LAMIVUDINA (3 TC) PARA TERAPIA ANTIRETROVIRAL DE ADULTOS COM INFECÇÃO POR HIV‐1 SEM TRATAMENTO PRÉVIO ‐ RESULTADO DE 3 ANOS DOS ESTUDOS GEMINI
- Author
-
Pedro Cahn, Juan Sierra Madero, José Ramón Arribas, Jörg Sievers, Choy Man, Rimgaile Urbaityte, Mark Underwood, Jean Andre Van Wyk, Kimberly Smith, and Roberto Zajdenverg
- Subjects
Infectious and parasitic diseases ,RC109-216 ,Microbiology ,QR1-502 - Published
- 2021
- Full Text
- View/download PDF
4. Duration of anti-tuberculosis therapy and timing of antiretroviral therapy initiation: association with mortality in HIV-related tuberculosis.
- Author
-
Claudia P Cortes, Firas H Wehbe, Catherine C McGowan, Bryan E Shepherd, Stephany N Duda, Cathy A Jenkins, Elsa Gonzalez, Gabriela Carriquiry, Mauro Schechter, Denis Padgett, Carina Cesar, Juan Sierra Madero, Jean W Pape, Daniel R Masys, Timothy R Sterling, and Caribbean, Central American, South American Network for HIV Research of the International Epidemiologic Databases to Evaluate AIDS
- Subjects
Medicine ,Science - Abstract
Antiretroviral therapy (ART) decreases mortality risk in HIV-infected tuberculosis patients, but the effect of the duration of anti-tuberculosis therapy and timing of anti-tuberculosis therapy initiation in relation to ART initiation on mortality, is unclear.We conducted a retrospective observational multi-center cohort study among HIV-infected persons concomitantly treated with Rifamycin-based anti-tuberculosis therapy and ART in Latin America. The study population included persons for whom 6 months of anti-tuberculosis therapy is recommended.Of 253 patients who met inclusion criteria, median CD4+ lymphocyte count at ART initiation was 64 cells/mm(3), 171 (68%) received >180 days of anti-tuberculosis therapy, 168 (66%) initiated anti-tuberculosis therapy before ART, and 43 (17%) died. In a multivariate Cox proportional hazards model that adjusted for CD4+ lymphocytes and HIV-1 RNA, tuberculosis diagnosed after ART initiation was associated with an increased risk of death compared to tuberculosis diagnosis before ART initiation (HR 2.40; 95% CI 1.15, 5.02; P = 0.02). In a separate model among patients surviving >6 months after tuberculosis diagnosis, after adjusting for CD4+ lymphocytes, HIV-1 RNA, and timing of ART initiation relative to tuberculosis diagnosis, receipt of >6 months of anti-tuberculosis therapy was associated with a decreased risk of death (HR 0.23; 95% CI 0.08, 0.66; P=0.007).The increased risk of death among persons diagnosed with tuberculosis after ART initiation highlights the importance of screening for tuberculosis before ART initiation. The decreased risk of death among persons receiving > 6 months of anti-tuberculosis therapy suggests that current anti-tuberculosis treatment duration guidelines should be re-evaluated.
- Published
- 2013
- Full Text
- View/download PDF
5. Rates and reasons for early change of first HAART in HIV-1-infected patients in 7 sites throughout the Caribbean and Latin America.
- Author
-
Carina Cesar, Bryan E Shepherd, Alejandro J Krolewiecki, Valeria I Fink, Mauro Schechter, Suely H Tuboi, Marcelo Wolff, Jean W Pape, Paul Leger, Denis Padgett, Juan Sierra Madero, Eduardo Gotuzzo, Omar Sued, Catherine C McGowan, Daniel R Masys, Pedro E Cahn, and Caribbean, Central and South America Network for HIV Research (CCASAnet) Collaboration of the International Epidemiologic Databases to Evaluate AIDS (IeDEA) Program
- Subjects
Medicine ,Science - Abstract
HAART rollout in Latin America and the Caribbean has increased from approximately 210,000 in 2003 to 390,000 patients in 2007, covering 62% (51%-70%) of eligible patients, with considerable variation among countries. No multi-cohort study has examined rates of and reasons for change of initial HAART in this region.Antiretroviral-naïve patients >or= 18 years who started HAART between 1996 and 2007 and had at least one follow-up visit from sites in Argentina, Brazil, Chile, Haiti, Honduras, Mexico and Peru were included. Time from HAART initiation to change (stopping or switching any antiretrovirals) was estimated using Kaplan-Meier techniques. Cox proportional hazards modeled the associations between change and demographics, initial regimen, baseline CD4 count, and clinical stage.Of 5026 HIV-infected patients, 35% were female, median age at HAART initiation was 37 years (interquartile range [IQR], 31-44), and median CD4 count was 105 cells/uL (IQR, 38-200). Estimated probabilities of changing within 3 months and one year of HAART initiation were 16% (95% confidence interval (CI) 15-17%) and 28% (95% CI 27-29%), respectively. Efavirenz-based regimens and no clinical AIDS at HAART initiation were associated with lower risk of change (hazard ratio (HR) = 1.7 (95% CI 1.1-2.6) and 2.1 (95% CI 1.7-2.5) comparing neverapine-based regimens and other regimens to efavirenz, respectively; HR = 1.3 (95% CI 1.1-1.5) for clinical AIDS at HAART initiation). The primary reason for change among HAART initiators were adverse events (14%), death (5.7%) and failure (1.3%) with specific toxicities varying among sites. After change, most patients remained in first line regimens.Adverse events were the leading cause for changing initial HAART. Predictors for change due to any reason were AIDS at baseline and the use of a non-efavirenz containing regimen. Differences between participant sites were observed and require further investigation.
- Published
- 2010
- Full Text
- View/download PDF
6. Clinical outcomes and risk factors for immune recovery and all‐cause mortality in Latin Americans living with HIV with virological success: a retrospective cohort study
- Author
-
Gabriel Castillo‐Rozas, Shengxin Tu, Paula Mendes Luz, Fernando Mejia, Juan Sierra‐Madero, Vanessa Rouzier, Bryan E. Shepherd, and Claudia P. Cortes
- Subjects
Caribbean Region ,CD4 lymphocyte count ,immune reconstitution ,Latin America ,morbidity ,non‐communicable diseases ,Immunologic diseases. Allergy ,RC581-607 - Abstract
Abstract Introduction Immune reconstitution following antiretroviral therapy (ART) initiation is crucial to prevent AIDS and non‐AIDS‐related comorbidities. Patients with suppressed viraemia who fail to restore cellular immunity are exposed to an increased risk of morbidity and mortality during long‐term follow‐up, although the underlying mechanisms remain poorly understood. We aim to describe clinical outcomes and factors associated with the worse immune recovery and all‐cause mortality in people living with HIV (PLWH) from Latin America following ART initiation. Methods Retrospective cohort study using the CCASAnet database: PLWH ≥18 years of age at ART initiation using a three drug‐based combination therapy and with medical follow‐up for ≥24 months after ART initiation and undetectable viral load were included. Patients were divided into four immune recovery groups based on rounded quartiles of increase in CD4 T‐cell count at 2 years of treatment (350 cells/mm3). Primary outcomes included all‐cause mortality, AIDS‐defining events and non‐communicable diseases that occurred >2 years after ART initiation. Factors associated with an increase in CD4 T‐cell count at 2 years of treatment were evaluated using a cumulative probability model with a logit link. Results In our cohort of 4496 Latin American PLWH, we found that patients with the lowest CD4 increase (
- Published
- 2024
- Full Text
- View/download PDF
7. Late-onset opportunistic infections while receiving anti-retroviral therapy in Latin America: burden and risk factors
- Author
-
Isaac Núñez, Brenda Crabtree-Ramirez, Bryan E. Shepherd, Timothy R. Sterling, Pedro Cahn, Valdiléa G. Veloso, Claudia P Cortes, Denis Padgett, Eduardo Gotuzzo, Juan Sierra-Madero, Catherine C. McGowan, Anna K. Person, and Yanink Caro-Vega
- Subjects
Opportunistic infections ,HIV ,AIDS ,Latin America ,Tuberculosis ,Cohort studies ,Infectious and parasitic diseases ,RC109-216 - Abstract
Objectives: The aim of this study was to describe the incidence, clinical characteristics, and risk factors of late-onset opportunistic infections (LOI) in people who live with HIV (PWLHA) within the Caribbean, Central and South America network for HIV epidemiology. Methods: We performed a retrospective cohort study including treatment-naive PWLHA enrolled at seven sites (Argentina, Brazil, Chile, Peru, Mexico, and two sites in Honduras). Follow-up began at 6 months after treatment started. Outcomes were LOI, loss to follow-up, and death. We used a Cox proportional hazards model and a competing risks model to evaluate risk factors. Results: A total of 10,583 patients were included. Median follow up was at 5.4 years. LOI occurred in 895 (8.4%) patients. Median time to opportunistic infection was 2.1 years. The most common infections were tuberculosis (39%), esophageal candidiasis (10%), and Pneumocystis jirovecii (P. jirovecii) pneumonia (10%). Death occurred in 576 (5.4%) patients, and 3021 (28.5%) patients were lost to follow-up.A protease inhibitor–based regimen (hazard ratio 1.25), AIDS-defining events during the first 6 months of antiretroviral-treatment (hazard ratio 2.12), starting antiretroviral-treatment in earlier years (hazard ratio 1.52 for 2005 vs 2010), and treatment switch (hazard ratio 1.31) were associated with a higher risk of LOI. Conclusion: LOI occurred in nearly one in 10 patients. People with risk factors could benefit from closer follow-up.
- Published
- 2022
- Full Text
- View/download PDF
8. Tuberculosis treatment intermittency in the continuation phase and mortality in HIV-positive persons receiving antiretroviral therapy
- Author
-
Brenda Crabtree-Ramirez, Cathy A. Jenkins, Bryan E. Shepherd, Karu Jayathilake, Valdilea G. Veloso, Gabriela Carriquiry, Eduardo Gotuzzo, Claudia P. Cortes, Dennis Padgett, Catherine McGowan, Juan Sierra-Madero, Serena Koenig, Jean W. Pape, Timothy R. Sterling, and the CCASAnet Region of IeDEA
- Subjects
Tuberculosis ,Tuberculosis treatment ,HIV ,Intermittent treatment ,ART ,TB maintenance treatment ,Infectious and parasitic diseases ,RC109-216 - Abstract
Abstract Background Some tuberculosis (TB) treatment guidelines recommend daily TB treatment in both the intensive and continuation phases of treatment in HIV-positive persons to decrease the risk of relapse and acquired drug resistance. However, guidelines vary across countries, and treatment is given 7, 5, 3, or 2 days/week. The effect of TB treatment intermittency in the continuation phase on mortality in HIV-positive persons on antiretroviral therapy (ART), is not well-described. Methods We conducted an observational cohort study among HIV-positive adults treated for TB between 2000 and 2018 and after enrollment into the Caribbean, Central, and South America network for HIV epidemiology (CCASAnet; Brazil, Chile, Haiti, Honduras, Mexico and Peru). All received standard TB therapy (2-month initiation phase of daily isoniazid, rifampin or rifabutin, pyrazinamide ± ethambutol) and continuation phase of isoniazid and rifampin or rifabutin, administered concomitantly with ART. Known timing of ART and TB treatment were also inclusion criteria. Kaplan–Meier and Cox proportional hazards methods compared time to death between groups. Missing model covariates were imputed via multiple imputation. Results 2303 patients met inclusion criteria: 2003(87%) received TB treatment 5–7 days/week and 300(13%) 2–3 days/week in the continuation phase. Intermittency varied by site: 100% of patients from Brazil and Haiti received continuation phase treatment 5–7 days/week, followed by Honduras (91%), Peru (42%), Mexico (7%), and Chile (0%). The crude risk of death was lower among those receiving treatment 5–7 vs. 2–3 days/week (HR = 0.68; 95% CI = 0.51—0.91; P = 0.008). After adjusting for age, sex, CD4, ART use at TB diagnosis, site of TB disease (pulmonary vs. extrapulmonary), and year of TB diagnosis, mortality risk was lower, but not significantly, among those treated 5–7 days/week vs. 2–3 days/week (HR 0.75, 95%CI 0.55–1.01; P = 0.06). After also stratifying by study site, there was no longer a protective effect (HR 1.42, 95%CI 0.83–2.45; P = 0.20). Conclusions TB treatment 5–7 days/week was associated with a marginally decreased risk of death compared to TB treatment 2–3 days/week in the continuation phase in multivariable, unstratified analyses. However, little variation in TB treatment intermittency within country meant the results could have been driven by other differences between study sites. Therefore, randomized trials are needed, especially in heterogenous regions such as Latin America.
- Published
- 2022
- Full Text
- View/download PDF
9. Prevención y control de la infección por coronavirus SARS-CoV-2 (Covid-19) en unidades de hemodiálisis
- Author
-
Olynka Vega-Vega, Mauricio Arvizu-Hernández, José Guillermo Domínguez-Cherit, Juan Sierra-Madero, and Ricardo Correa-Rotter
- Subjects
hemodiálisis ,prevención primaria ,pandemia ,infección por coronavirus ,recomendaciones ,Public aspects of medicine ,RA1-1270 - Abstract
La pandemia del SARS-CoV-2 representa un riesgo especial para los pacientes en hemodiálisis crónica por su estado de inmunosupresión, edad avanzada y coexistencia de comorbilidades importantes, en particular patología cardiovascular, diabetes mellitus y otras. Adicionalmente, esta población constituye un conglomerado cerrado ya que los pacientes acuden a tratamiento con regularidad y permanecen horas en los lugares de tratamiento, expuestos a una posible adquisición de la infección. El hecho de acudir necesaria y regularmente a su tratamiento impide que permanezcan en aislamiento domiciliario y con exposición potencial en el traslado. Las presentes recomendaciones resumen las intervenciones propuestas por tres organizaciones internacionales, a las que se agregan algunas sugeridas por expertos nacionales, con el objetivo de identificar precozmente a los pacientes y personal de la salud en riesgo para disminuir el riesgo de infección.
- Published
- 2020
- Full Text
- View/download PDF
10. Health outcomes among HIV‐positive Latinos initiating antiretroviral therapy in North America versus Central and South America
- Author
-
Carina Cesar, John R Koethe, Mark J Giganti, Peter Rebeiro, Keri N Althoff, Sonia Napravnik, Angel Mayor, Beatriz Grinsztejn, Marcelo Wolff, Denis Padgett, Juan Sierra‐Madero, Eduardo Gotuzzo, Timothy R Sterling, James Willig, Julie Levison, Mari Kitahata, Maria C Rodriguez‐Barradas, Richard D Moore, Catherine McGowan, Bryan E Shepherd, Pedro Cahn, and for the Caribbean, Central and South America Network for HIV epidemiology (CCASAnet) and the North American AIDS Cohort Collaboration on Research and Design (NA‐ACCORD)
- Subjects
HIV ,antiretroviral therapy ,highly active ,mortality ,Latin America ,North America ,Immunologic diseases. Allergy ,RC581-607 - Abstract
Introduction Latinos living with HIV in the Americas share a common ethnic and cultural heritage. In North America, Latinos have a relatively high rate of new HIV infections but lower rates of engagement at all stages of the care continuum, whereas in Latin America antiretroviral therapy (ART) services continue to expand to meet treatment needs. In this analysis, we compare HIV treatment outcomes between Latinos receiving ART in North America versus Latin America. Methods HIV‐positive adults initiating ART at Caribbean, Central and South America Network for HIV (CCASAnet) sites were compared to Latino patients (based on country of origin or ethnic identity) starting treatment at North American AIDS Cohort Collaboration on Research and Design (NA‐ACCORD) sites in the United States and Canada between 2000 and 2011. Cox proportional hazards models compared mortality, treatment interruption, antiretroviral regimen change, virologic failure and loss to follow‐up between cohorts. Results The study included 8400 CCASAnet and 2786 NA‐ACCORD patients initiating ART. CCASAnet patients were younger (median 35 vs. 37 years), more likely to be female (27% vs. 20%) and had lower nadir CD4 count (median 148 vs. 195 cells/µL, p
- Published
- 2016
- Full Text
- View/download PDF
11. A picture is worth a thousand words: maps of HIV indicators to inform research, programs, and policy from NA‐ACCORD and CCASAnet clinical cohorts
- Author
-
Keri N Althoff, Peter F Rebeiro, David B Hanna, Denis Padgett, Michael A Horberg, Beatriz Grinsztejn, Alison G Abraham, Robert Hogg, M John Gill, Marcelo J Wolff, Angel Mayor, Anita Rachlis, Carolyn Williams, Timothy R Sterling, Mari M Kitahata, Kate Buchacz, Jennifer E Thorne, Carina Cesar, Fernando M Cordero, Sean B Rourke, Juan Sierra‐Madero, Jean W Pape, Pedro Cahn, Catherine McGowan, and for the North American Aids Cohort Collaboration on Research and Design (na‐Accord) and the Caribbean, Central and the South America Network for Hiv Epidemiology (ccasanet)
- Subjects
Map ,HIV indicators ,CD4 T‐lymphocyte count ,retention in care ,antiretroviral therapy ,HIV RNA suppression ,Immunologic diseases. Allergy ,RC581-607 - Abstract
Introduction Maps are powerful tools for visualization of differences in health indicators by geographical region, but multi‐country maps of HIV indicators do not exist, perhaps due to lack of consistent data across countries. Our objective was to create maps of four HIV indicators in North, Central, and South American countries. Methods Using data from the North American AIDS Cohort Collaboration on Research and Design (NA‐ACCORD) and the Caribbean, Central, and South America network for HIV epidemiology (CCASAnet), we mapped median CD4 at presentation for HIV clinical care, proportion retained in HIV primary care, proportion prescribed antiretroviral therapy (ART), and the proportion with suppressed plasma HIV viral load (VL) from 2010 to 2012 for North, Central, and South America. The 15 Canadian and US clinical cohorts and 7 clinical cohorts in Argentina, Brazil, Chile, Haiti, Honduras, Mexico, and Peru represented approximately 2–7% of persons known to be living with HIV in these countries. Results Study populations were selected for each indicator: median CD4 at presentation for care was estimated among 14,811 adults; retention was estimated among 87,979 adults; ART use was estimated among 84,757 adults; and suppressed VL was estimated among 51,118 adults. Only three US states and the District of Columbia had a median CD4 at presentation >350 cells/mm3. Haiti, Mexico, and several states had >85% retention in care; lower (50–74%) retention in care was observed in the US West, South, and Mid‐Atlantic, and in Argentina, Brazil, and Peru. ART use was highest (90%) in Mexico. The percentages of patients with suppressed VL in the US South and Northeast were lower than in most of Central and South America. Conclusions These maps provide visualization of gaps in the quality of HIV care and allow for comparison between and within countries as well as monitoring policy and programme goals within geographical boundaries.
- Published
- 2016
- Full Text
- View/download PDF
12. Time to HAART Initiation after Diagnosis and Treatment of Opportunistic Infections in Patients with AIDS in Latin America.
- Author
-
Brenda Crabtree-Ramírez, Yanink Caro-Vega, Bryan E Shepherd, Beatriz Grinsztejn, Marcelo Wolff, Claudia P Cortes, Denis Padgett, Gabriela Carriquiry, Valeria Fink, Karu Jayathilake, Anna K Person, Catherine McGowan, Juan Sierra-Madero, and Caribbean, Central and South America Network for HIV Epidemiology (CCASAnet), of the International Epidemiologic Databases to Evaluate AIDS (IeDEA) Program
- Subjects
Medicine ,Science - Abstract
BACKGROUND:Since 2009, earlier initiation of highly active antiretroviral therapy (HAART) after an opportunistic infection (OI) has been recommended based on lower risks of death and AIDS-related progression found in clinical trials. Delay in HAART initiation after OIs may be an important barrier for successful outcomes in patients with advanced disease. Timing of HAART initiation after an OI in "real life" settings in Latin America has not been evaluated. METHODS:Patients in the Caribbean, Central and South America network for HIV Epidemiology (CCASAnet) ≥18 years of age at enrolment, from 2001-2012 who had an OI before HAART initiation were included. Patients were divided in an early HAART (EH) group (those initiating within 4 weeks of an OI) and a delayed HAART (DH) group (those initiating more than 4 weeks after an OI). All patients with an AIDS-defining OI were included. In patients with more than one OI the first event reported was considered. Calendar trends in the proportion of patients in the EH group (before and after 2009) were estimated by site and for the whole cohort. Factors associated with EH were estimated using multivariable logistic regression models. RESULTS:A total of 1457 patients had an OI before HAART initiation and were included in the analysis: 213 from Argentina, 686 from Brazil, 283 from Chile, 119 from Honduras and 156 from Mexico. Most prevalent OI were Tuberculosis (31%), followed by Pneumocystis pneumonia (24%), Invasive Candidiasis (16%) and Toxoplasmosis (9%). Median time from OI to HAART initiation decreased significantly from 5.7 (interquartile range [IQR] 2.8-12.1) weeks before 2009 to 4.3 (IQR 2.0-7.1) after 2009 (p
- Published
- 2016
- Full Text
- View/download PDF
13. Comparing the efficacy of efavirenz and boosted lopinavir using viremia copy‐years
- Author
-
Viviane D Lima, Juan Sierra‐Madero, Zunyou Wu, Joel Singer, Evan Wood, Mark W Hull, Paul Richard Harrigan, and Julio SG Montaner
- Subjects
HIV‐1 plasma viral load ,antiretroviral therapy ,clinical trial ,area under the curve ,cumulative viremia ,efficacy ,Immunologic diseases. Allergy ,RC581-607 - Abstract
Introduction HIV‐1 plasma viral load during treatment can be highly variable. Thus, there is the need to find a measure of cumulative viremia that can be used to assess both the short‐ and long‐term efficacy of highly active antiretroviral therapy (HAART). Here, we validate a measure of cumulative viremia to evaluate HAART efficacy. Methods We accessed HAART efficacy using data from a randomized clinical trial conducted in Mexico. We compared the proportion of individuals achieving a viral load
- Published
- 2014
- Full Text
- View/download PDF
14. Pilot, randomized study assessing safety, tolerability and efficacy of simplified LPV/r maintenance therapy in HIV patients on the 1 PI-based regimen.
- Author
-
Pedro Cahn, Julio Montaner, Patrice Junod, Patricia Patterson, Alejandro Krolewiecki, Jaime Andrade-Villanueva, Isabel Cassetti, Juan Sierra-Madero, Arnaldo David Casiró, Raul Bortolozzi, Sergio Horacio Lupo, Nadia Longo, Emmanouil Rampakakis, Nabil Ackad, and John S Sampalis
- Subjects
Medicine ,Science - Abstract
To compare the efficacy and safety of an individualized treatment-simplification strategy consisting of switching from a highly-active anti-retroviral treatment (HAART) with a ritonavir-boosted protease inhibitor (PI/r) and 2 nucleoside reverse-transcriptase inhibitors (NRTIs) to lopinavir/ritonavir (LPV/r) monotherapy, with intensification by 2 NRTIs if necessary, to that of continuing their HAART.This is a one-year, randomized, open-label, multi-center study in virologically-suppressed HIV-1-infected adults on their first PI/r-containing treatment, randomized to either LPV/r-monotherapy or continue their current treatment. Treatment efficacy was determined by plasma HIV-1 RNA viral load (VL), time-to-virologic rebound, patient-reported outcomes (PROs) and CD4+T-cell-count changes. Safety was assessed with the incidence of treatment-emergent adverse events (AE).Forty-one patients were randomized to LPV/r and 39 to continue their HAART. No statistically-significant differences between the two study groups in demographics and baseline characteristics were observed. At day-360, 71(39:LPV/r;32:HAART) patients completed treatment, while 9(2:LPV/r;7:HAART) discontinued. In a Last Observation Carried Forward Intent-to-Treat analysis, 40(98%) patients on LPV/r and 37(95%) on HAART had VL
- Published
- 2011
- Full Text
- View/download PDF
15. Acetylcholine-Esterase Inhibitor Pyridostigmine Decreases T Cell Overactivation in Patients Infected by HIV.
- Author
-
Sergio Iván Valdés-Ferrer, José C. Crispín, Pablo Francisco Belaunzarán, Carlos G. Cantú-Brito, Juan Sierra-Madero, and Jorge Alcocer-Varela
- Abstract
AbstractHIV infection is characterized by persistent immune activation, increased production of proinflammatory cytokines, and rapid T cell turnover. The autonomic nervous system exerts a regulatory effect on the inflammatory response mediated by acetylcholine. We investigated whether an acetylcholine esterase inhibitor would diminish the T cell overactive phenotype characteristic of chronically infected HIV patients. We carried out a proof-of-concept, placebo-controlled study involving 19 subjects chronically infected with HIV-1. Nine patient received pyridostigmine and 10 took a placebo. T cell activation measured by expression of CD69 (p= 0.025) diminished in those taking pyridostigmine. The drug also diminished in vitroT cell proliferation induced by PMA and ionomycin (p= 0.026). IFN-γ release was diminished in the pyridostigmine group (p= 0.016) and expression of IL-4 (p= 0.010) and IL-10 (p= 0.015) increased. Here we showed that pyridostigmine is able to modify T cell overactivation and proliferation in patients chronically infected with HIV. Pyridostigmine led to an increase in the antiinflammatory cytokine IL-10 and a decrease in T cell proliferation and production of the proinflammatory cytokine IFN-γ. [ABSTRACT FROM AUTHOR]
- Published
- 2009
16. Synchronous Kinetics of CD4+ Lymphocytes and Viral Loadbefore the Onset of Oral Candidosis and Hairy Leukoplakia ina Cohort of Mexican HIV-Infected Patients.
- Author
-
Velia Ramírez-Amador, Sergio Ponce-De-León, Juan Sierra-Madero, Luis Soto-Ramírez, Lilly Esquivel-Pedraza, and Gabriela Anaya-Saavedra
- Published
- 2005
17. The Changing Clinical Spectrum of Human Immunodeficiency Virus (HIV)-Related Oral Lesions in 1,000 Consecutive Patients: A 12-Year Study in a Referral Center in Mexico.
- Author
-
Velia Ramírez-Amador, Lilly Esquivel-Pedraza, Juan Sierra-Madero, Gabriela Anaya-Saavedra, Imelda González-Ramírez, and Sergio Ponce-de-León
- Published
- 2003
- Full Text
- View/download PDF
18. Pyridostigmine reduces mortality of patients with severe SARS-CoV-2 infection: A phase 2/3 randomized controlled trial
- Author
-
Sergio Fragoso-Saavedra, Isaac Núñez, Belem M. Audelo-Cruz, Sarahi Arias-Martínez, Daniel Manzur-Sandoval, Alejandro Quintero-Villegas, H. Benjamín García-González, Sergio L. Carbajal-Morelos, Sergio PoncedeLeón-Rosales, José Gotés-Palazuelos, José A. Maza-Larrea, J. Javier Rosales-de la Rosa, Dafne Diaz-Rivera, Edgar Luna-García, Elvira Piten-Isidro, Perla M. Del Río-Estrada, Mario Fragoso-Saavedra, Yanink Caro-Vega, Isabella Batina, León Islas-Weinstein, David A. Iruegas-Nunez, Juan J. Calva, Pablo F. Belaunzarán-Zamudio, Juan Sierra-Madero, José C. Crispín, and Sergio Iván Valdés-Ferrer
- Subjects
COVID-19 ,SARS-CoV-2 ,Mortality ,Invasive mechanical ventilation ,Immunomodulation ,Pyridostigmine ,Therapeutics. Pharmacology ,RM1-950 ,Biochemistry ,QD415-436 - Abstract
Abstract: Background: Respiratory failure in severe coronavirus disease 2019 (COVID-19) is associated with a severe inflammatory response. Acetylcholine (ACh) reduces systemic inflammation in experimental bacterial and viral infections. Pyridostigmine increases the half-life of endogenous ACh, potentially reducing systemic inflammation. We aimed to determine if pyridostigmine decreases a composite outcome of invasive mechanical ventilation (IMV) and death in adult patients with severe COVID-19. Methods: We performed a double-blinded, placebo-controlled, phase 2/3 randomized controlled trial of oral pyridostigmine (60 mg/day) or placebo as add-on therapy in adult patients admitted due to confirmed severe COVID-19 not requiring IMV at enrollment. The primary outcome was a composite of IMV or death by day 28. Secondary outcomes included reduction of inflammatory markers and circulating cytokines, and 90-day mortality. Adverse events (AEs) related to study treatment were documented and described. Results: We recruited 188 participants (94 per group); 112 (59.6%) were men; the median (IQR) age was 52 (44–64) years. The study was terminated early due to a significant reduction in the primary outcome in the treatment arm and increased difficulty with recruitment. The primary outcome occurred in 22 (23.4%) participants in the placebo group vs. 11 (11.7%) in the pyridostigmine group (hazard ratio, 0.47, 95% confidence interval 0.24–0.9; P = 0.03). This effect was driven by a reduction in mortality (19 vs. 8 deaths, respectively). Conclusion: Our data indicate that adding pyridostigmine to standard care reduces mortality among patients hospitalized for severe COVID-19.
- Published
- 2022
- Full Text
- View/download PDF
19. A parallel-group, multicenter randomized, double-blinded, placebo-controlled, phase 2/3, clinical trial to test the efficacy of pyridostigmine bromide at low doses to reduce mortality or invasive mechanical ventilation in adults with severe SARS-CoV-2 infection: the Pyridostigmine In Severe COvid-19 (PISCO) trial protocol
- Author
-
Sergio Fragoso-Saavedra, David A. Iruegas-Nunez, Alejandro Quintero-Villegas, H. Benjamín García-González, Isaac Nuñez, Sergio L. Carbajal-Morelos, Belem M. Audelo-Cruz, Sarahi Arias-Martínez, Yanink Caro-Vega, Juan José Calva, Verónica Luqueño-Martínez, Alejandra González-Duarte, Brenda Crabtree-Ramírez, José C. Crispín, Juan Sierra-Madero, Pablo F. Belaunzarán-Zamudio, and Sergio I. Valdés-Ferrer
- Subjects
COVID-19 ,SARS-Cov-2 ,Mortality ,Invasive mechanical ventilation ,Immunomodulation ,Pyridostigmine ,Infectious and parasitic diseases ,RC109-216 - Abstract
Abstract Background Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, the causative agent of coronavirus disease 2019 (COVID-19), may lead to severe systemic inflammatory response, pulmonary damage, and even acute respiratory distress syndrome (ARDS). This in turn may result in respiratory failure and in death. Experimentally, acetylcholine (ACh) modulates the acute inflammatory response, a neuro-immune mechanism known as the inflammatory reflex. Recent clinical evidence suggest that electrical and chemical stimulation of the inflammatory reflex may reduce the burden of inflammation in chronic inflammatory diseases. Pyridostigmine (PDG), an ACh-esterase inhibitor (i-ACh-e), increases the half-life of endogenous ACh, therefore mimicking the inflammatory reflex. This clinical trial is aimed at evaluating if add-on of PDG leads to a decrease of invasive mechanical ventilation and death among patients with severe COVID-19. Methods A parallel-group, multicenter, randomized, double-blinded, placebo-controlled, phase 2/3 clinical trial to test the efficacy of pyridostigmine bromide 60 mg/day P.O. to reduce the need for invasive mechanical ventilation and mortality in hospitalized patients with severe COVID-19. Discussion This study will provide preliminary evidence of whether or not -by decreasing systemic inflammation- add-on PDG can improve clinical outcomes in patients with severe COVID-19. Trial registration ClinicalTrials.gov NCT04343963 (registered on April 14, 2020).
- Published
- 2020
- Full Text
- View/download PDF
20. Effect of Tocilizumab in Mortality among Patients with Severe and Critical Covid-19: Experience in a Third-Level Medical Center
- Author
-
Bernardo A. Martinez-Guerra, Nereyda A. de-León-Cividanes, Karla M. Tamez-Torres, Carla M. Román-Montes, Sandra Rajme-López, Edgar Ortiz-Brizuela, Carlos A. Aguilar-Salinas, Juan Sierra-Madero, José Sifuentes-Osornio, Alfredo Ponce-de-León, and María F. González-Lara
- Subjects
Tocilizumab. COVID-19. SARS-CoV-2. Mexico. ,Internal medicine ,RC31-1245 - Abstract
Background: Trials evaluating safety and efficacy of tocilizumab in coronavirus disease 19 (COVID-19) show contradictory results. Objective: The objective of the study was to evaluate the effect of tocilizumab in hospital mortality among patients with severe COVID-19 in a third-level medical center. Methods: This prospective cohort study included patients with severe and critical COVID-19. Primary outcome was death during hospitalization. Secondary outcomes included invasive mechanical ventilation (IMV), days on IMV, ventilator-free days (VFDs), length of hospital stay (LOS), and development of hospitalacquired infections (HAIs). Bivariate, multivariate, and propensity score matching analysis were performed. Results: During the study period, 99/794 (12%) patients received tocilizumab. Male patients, health care workers, and patients with increased inflammatory markers received tocilizumab more frequently. No difference in hospital mortality was observed between groups (34% vs. 34%, p = 0.98). Tocilizumab was not independently associated with mortality. No significant treatment effects were observed in propensity score analysis. IMV was more frequent (46% vs. 11%, p < 0.01) and LOS was longer (12 vs. 7 days, p < 0.01) in the tocilizumab group, reflecting increased severity. Although HAIs were more frequent in the tocilizumab group (22% vs. 10%, p < 0.01), no difference was seen after adjusting for IMV (38% vs. 40%, p = 0.86). Conclusions: In our study, tocilizumab was not associated with decreased hospital mortality among patients with severe COVID-19.
- Published
- 2022
- Full Text
- View/download PDF
21. Differences in response to antiretroviral therapy in HIV-positive patients being treated for tuberculosis in Eastern Europe, Western Europe and Latin America
- Author
-
Yanink Caro-Vega, Anna Schultze, Anne Marie W. Efsen, Frank A. Post, Alexander Panteleev, Aliaksandr Skrahin, Jose M. Miro, Enrico Girardi, Daria N. Podlekareva, Jens D. Lundgren, Juan Sierra-Madero, Javier Toibaro, Jaime Andrade-Villanueva, Simona Tetradov, Jan Fehr, Joan Caylà, Marcelo H. Losso, Robert F. Miller, Amanda Mocroft, Ole Kirk, and Brenda Crabtree-Ramírez
- Subjects
HIV ,Tuberculosis ,ART ,Efavirenz ,Protease inhibitor ,Outcomes ,Infectious and parasitic diseases ,RC109-216 - Abstract
Abstract Background Efavirenz-based antiretroviral therapy (ART) regimens are preferred for treatment of adult HIV-positive patients co-infected with tuberculosis (HIV/TB). Few studies have compared outcomes among HIV/TB patients treated with efavirenz or non-efavirenz containing regimens. Methods HIV-positive patients aged ≥16 years with a diagnosis of tuberculosis recruited to the TB:HIV study between Jan 1, 2011, and Dec 31, 2013 in 19 countries in Eastern Europe (EE), Western Europe (WE), and Latin America (LA) who received ART concomitantly with TB treatment were included. Patients either received efavirenz-containing ART starting between 15 days prior to, during, or within 90 days after starting tuberculosis treatment, (efavirenz group), or other ART regimens (non-efavirenz group). Patients who started ART more than 90 days after initiation of TB treatment, or who experienced ART interruption of more than 15 days during TB treatment were excluded. We describe rates and factors associated with death, virological suppression, and loss to follow up at 12 months using univariate, multivariate Cox, and marginal structural models to compare the two groups of patients. Results Of 965 patients (647 receiving efavirenz-containing ART, and 318 a non-efavirenz regimen) 50% were from EE, 28% from WE, and 22% from LA. Among those not receiving efavirenz-containing ART, regimens mainly contained a ritonavir-boosted protease inhibitor (57%), or raltegravir (22%). At 12 months 1.4% of patients in WE had died, compared to 20% in EE: rates of virological suppression ranged from 21% in EE to 61% in WE. After adjusting for potential confounders, rates of death (adjusted Hazard Ratio; aHR, 95%CI: 1.13, 0.72–1.78), virological suppression (aHR, 95%CI: 0.97, 0.76–1.22), and loss to follow up (aHR, 95%CI: 1.17, 0.81–1.67), were similar in patients treated with efavirenz and non-efavirenz containing ART regimens. Conclusion In this large, prospective cohort, the response to ART varied significantly across geographical regions, whereas the ART regimen (efavirenz or non-efavirenz containing) did not impact on the proportion of patients who were virologically-suppressed, lost to follow up or dead at 12 months.
- Published
- 2018
- Full Text
- View/download PDF
22. Add-on Pyridostigmine Enhances CD4+ T-Cell Recovery in HIV-1-Infected Immunological Non-Responders: A Proof-of-Concept Study
- Author
-
Sergio I. Valdés-Ferrer, José C. Crispín, Pablo F. Belaunzarán-Zamudio, Carlos A. Rodríguez-Osorio, Bernardo Cacho-Díaz, Jorge Alcocer-Varela, Carlos Cantú-Brito, and Juan Sierra-Madero
- Subjects
HIV ,pyridostigmine ,CD4+ T-cell ,immune reconstitution ,cholinergic anti-inflammatory pathway ,Immunologic diseases. Allergy ,RC581-607 - Abstract
BackgroundIn human immunodeficiency virus (HIV)-infection, persistent T-cell activation leads to rapid turnover and increased cell death, leading to immune exhaustion and increased susceptibility to opportunistic infections. Stimulation of the vagus nerve increases acetylcholine (ACh) release and modulates inflammation in chronic inflammatory conditions, a neural mechanism known as the cholinergic anti-inflammatory pathway (CAP). Pyridostigmine (PDG), an ACh-esterase inhibitor, increases the half-life of endogenous ACh, therefore mimicking the CAP. We have previously observed that PDG reduces ex vivo activation and proliferation of T-cells obtained from people living with HIV.MethodsWe conducted a 16-week proof-of-concept open trial using PDG as add-on therapy in seven HIV-infected patients with discordant immune response receiving combined antiretroviral therapy, to determine whether PDG would promote an increase in total CD4+ T-cells. The trial was approved by the Institutional Research and Ethics Board and registered in ClinicalTrials.gov (NCT00518154).ResultsSeven patients were enrolled after signing informed consent forms. We observed that addition of PDG induced a significant increase in total CD4+ T-cells (baseline = 153.1 ± 43.1 vs. week-12 = 211.9 ± 61.1 cells/µL; p = 0.02). Post hoc analysis showed that in response to PDG, four patients (57%) significantly increased CD4+ T-cell counts (responders = 257.8 ± 26.6 vs. non-responders = 150.6 ± 18.0 cells/µL; p = 0.002), and the effect persisted for at least 1 year after discontinuation of PDG.ConclusionOur data indicate that in patients with HIV, add-on PDG results in a significant and persistent increase in circulating CD4+ T-cells.
- Published
- 2017
- Full Text
- View/download PDF
23. A decade of HAART in Latin America: Long term outcomes among the first wave of HIV patients to receive combination therapy.
- Author
-
Marcelo J Wolff, Mark J Giganti, Claudia P Cortes, Pedro Cahn, Beatriz Grinsztejn, Jean W Pape, Denis Padgett, Juan Sierra-Madero, Eduardo Gotuzzo, Stephany N Duda, Catherine C McGowan, Bryan E Shepherd, and Caribbean, Central and South America Network for HIV Epidemiology
- Subjects
Medicine ,Science - Abstract
In Latin America, the first wave of HIV-infected patients initiated highly active antiretroviral therapy (HAART) 10 or more years ago. Characterizing their treatment experience and corresponding outcomes across a decade of HAART may yield insights relevant to the ongoing care of such patients and those initiating HAART more recently in similar clinical settings.This retrospective study included adults initiating HAART before 2004 at 8 sites in Argentina, Brazil, Chile, Haiti, Honduras, and Mexico. Patient status (in care, dead, or lost to follow-up [LTFU]) was assessed at 6-month intervals for 10 years, along with CD4 count and HIV-1 viral load (VL) for patients in care.4,975 patients (66% male) started HAART prior to 2004; 45% were not antiretroviral-naïve. At 1, 5, and 10 years, rates of mortality were 4.2%, 9.0%, and 13.6% respectively. LTFU rates for the same periods were 2.4%, 10.9%, and 24.2%. Among patients remaining in care at 10 years, 84.4% were estimated to have VL≤400 copies/mL (Haiti excluded) and median baseline CD4 increased from 158 to 525 cells/mm3. Only 11.4% of all patients remained on their first regimen, 12.6% were on their second, 11.5% were on their third, and 23.0% were on their fourth or subsequent regimen. Outcomes were generally better for patients who were not antiretroviral-naïve, except for viral suppression. Heterogeneity among sites was substantial.Despite advanced disease and predominant use of older antiretrovirals, a large percentage of early HAART initiators in this Latin American cohort were alive and in care with sustained virologic suppression and progressive immune recovery after 10 years.
- Published
- 2017
- Full Text
- View/download PDF
24. High prevalence of late diagnosis of HIV in Mexico during the HAART era
- Author
-
Brenda Crabtree-Ramírez, Yanink Caro-Vega, Francisco Belaunzarán-Zamudio, and Juan Sierra-Madero
- Subjects
diagnóstico tardío ,VIH ,factores de riesgo ,México ,Delayed diagnosis ,HIV ,risk factors ,Mexico ,Public aspects of medicine ,RA1-1270 - Abstract
OBJECTIVE: To evaluate the prevalence of late HIV diagnosis (CD4OBJETIVO: Estimar la prevalencia de diagnóstico tardío (DT) (CD4
- Published
- 2012
25. Estimating the Impact of Earlier ART Initiation and Increased Testing Coverage on HIV Transmission among Men Who Have Sex with Men in Mexico using a Mathematical Model.
- Author
-
Yanink Caro-Vega, Carlos del Rio, Viviane Dias Lima, Malaquias Lopez-Cervantes, Brenda Crabtree-Ramirez, Sergio Bautista-Arredondo, M Arantxa Colchero, and Juan Sierra-Madero
- Subjects
Medicine ,Science - Abstract
To estimate the impact of late ART initiation on HIV transmission among men who have sex with men (MSM) in Mexico.An HIV transmission model was built to estimate the number of infections transmitted by HIV-infected men who have sex with men (MSM-HIV+) MSM-HIV+ in the short and long term. Sexual risk behavior data were estimated from a nationwide study of MSM. CD4+ counts at ART initiation from a representative national cohort were used to estimate time since infection. Number of MSM-HIV+ on treatment and suppressed were estimated from surveillance and government reports. Status quo scenario (SQ), and scenarios of early ART initiation and increased HIV testing were modeled.We estimated 14239 new HIV infections per year from MSM-HIV+ in Mexico. In SQ, MSM take an average 7.4 years since infection to initiate treatment with a median CD4+ count of 148 cells/mm3(25th-75th percentiles 52-266). In SQ, 68% of MSM-HIV+ are not aware of their HIV status and transmit 78% of new infections. Increasing the CD4+ count at ART initiation to 350 cells/mm3 shortened the time since infection to 2.8 years. Increasing HIV testing to cover 80% of undiagnosed MSM resulted in a reduction of 70% in new infections in 20 years. Initiating ART at 500 cells/mm3 and increasing HIV testing the reduction would be of 75% in 20 years.A substantial number of new HIV infections in Mexico are transmitted by undiagnosed and untreated MSM-HIV+. An aggressive increase in HIV testing coverage and initiating ART at a CD4 count of 500 cells/mm3 in this population would significantly benefit individuals and decrease the number of new HIV infections in Mexico.
- Published
- 2015
- Full Text
- View/download PDF
26. A Cross-Sectional Study of Prisoners in Mexico City Comparing Prevalence of Transmissible Infections and Chronic Diseases with That in the General Population.
- Author
-
Sergio Bautista-Arredondo, Andrea González, Edson Servan-Mori, Fenella Beynon, Luis Juarez-Figueroa, Carlos J Conde-Glez, Nathalie Gras, Juan Sierra-Madero, Ruy Lopez-Ridaura, Patricia Volkow, and Stefano M Bertozzi
- Subjects
Medicine ,Science - Abstract
To describe patterns of transmissible infections, chronic illnesses, socio-demographic characteristics and risk behaviors in Mexico City prisons, including in comparison to the general population, to identify those currently needing healthcare and inform policy.A cross-sectional study among 17,000 prisoners at 4 Mexico City prisons (June to December 2010). Participation was voluntary, confidential and based on informed consent. Participants were tested for HIV, Hepatitis B & C, syphilis, hypertension, obesity, and, if at risk, glucose and cholesterol. A subset completed a questionnaire on socio-demographic characteristics and risk behaviors. Positive results were delivered with counseling and treatment or referral.76.8% (15,517/20,196) of men and 92.9% (1,779/1,914) of women participated. Complete data sets were available for 98.8%. The following prevalence data were established for transmissible infections: HIV 0.7%; syphilis: Anti-TP+/VDRL+ 2.0%; Hepatitis B: HBcAb 2.8%, HBsAg 0.15%; Anti-HCV 3.2%. Obesity: 9.5% men, 33.8% women. Compared with national age- and sex-matched data, the relative prevalence was greater for HIV and syphilis among women, HIV and Hepatitis C in men, and all infections in younger participants. Obesity prevalence was similar for women and lower among male participants. The prevalence of previously diagnosed diabetes and hypertension was lower. Questionnaire data (1,934 men, 520 women) demonstrated lower educational levels, increased smoking and substance use compared to national data. High levels of non-sterile tattooing, physical abuse and histories of sexual violence were found.The study identified that health screening is acceptable to Mexico City prisoners and feasible on a large-scale. It demonstrated higher prevalence of HIV and other infections compared to national data, though low rates compared to international data. Individual participants benefited from earlier diagnosis, treatment and support. The data collected will also enable the formulation of improved policy for this vulnerable group.
- Published
- 2015
- Full Text
- View/download PDF
27. Did Universal Access to ARVT in Mexico Impact Suboptimal Antiretroviral Prescriptions?
- Author
-
Yanink Caro-Vega, Patricia Volkow, Juan Sierra-Madero, M. Arantxa Colchero, Brenda Crabtree-Ramírez, and Sergio Bautista-Arredondo
- Subjects
Immunologic diseases. Allergy ,RC581-607 - Abstract
Background. Universal access to antiretroviral therapy (ARVT) started in Mexico in 2001; no evaluation of the features of ARVT prescriptions over time has been conducted. The aim of the study is to document trends in the quality of ARVT-prescription before and after universal access. Methods. We describe ARVT prescriptions before and after 2001 in three health facilities from the following subsystems: the Mexican Social Security (IMSS), the Ministry of Health (SSA), and National Institutes of Health (INS). Combinations of drugs and reasons for change were classified according to current Mexican guidelines and state-of-the-art therapy. Comparisons were made using χ2 tests. Results. Before 2001, 29% of patients starting ARVT received HAART; after 2001 it increased to 90%. The proportion of adequate prescriptions decreased within the two periods of study in all facilities (P value < 0.01). The INS and SSA were more likely to be prescribed adequately (P value < 0.01) compared to IMSS. The distribution of reasons for change was not significantly different during this time for all facilities (P value > 0.05). Conclusions. Universal ARVT access in Mexico was associated with changes in ARVT-prescription patterns over time. Health providers’ performance improved, but not homogeneously. Training of personnel and guidelines updating is essential to improve prescription.
- Published
- 2013
- Full Text
- View/download PDF
28. Cross-sectional analysis of late HAART initiation in Latin America and the Caribbean: late testers and late presenters.
- Author
-
Brenda Crabtree-Ramírez, Yanink Caro-Vega, Bryan E Shepherd, Firas Wehbe, Carina Cesar, Claudia Cortés, Denis Padgett, Serena Koenig, Eduardo Gotuzzo, Pedro Cahn, Catherine McGowan, Daniel Masys, Juan Sierra-Madero, and CCASAnet Team
- Subjects
Medicine ,Science - Abstract
Starting HAART in a very advanced stage of disease is assumed to be the most prevalent form of initiation in HIV-infected subjects in developing countries. Data from Latin America and the Caribbean is still lacking. Our main objective was to determine the frequency, risk factors and trends in time for being late HAART initiator (LHI) in this region.Cross-sectional analysis from 9817 HIV-infected treatment-naïve patients initiating HAART at 6 sites (Argentina, Chile, Haiti, Honduras, Peru and Mexico) from October 1999 to July 2010. LHI had CD4(+) count ≤200 cells/mm(3) prior to HAART. Late testers (LT) were those LHI who initiated HAART within 6 months of HIV diagnosis. Late presenters (LP) initiated after 6 months of diagnosis. Prevalence, risk factors and trends over time were analyzed.Among subjects starting HAART (n = 9817) who had baseline CD4(+) available (n = 8515), 76% were LHI: Argentina (56%[95%CI:52-59]), Chile (80%[95%CI:77-82]), Haiti (76%[95%CI:74-77]), Honduras (91%[95%CI:87-94]), Mexico (79%[95%CI:75-83]), Peru (86%[95%CI:84-88]). The proportion of LHI statistically changed over time (except in Honduras) (p≤0.02; Honduras p = 0.7), with a tendency towards lower rates in recent years. Males had increased risk of LHI in Chile, Haiti, Peru, and in the combined site analyses (CSA). Older patients were more likely LHI in Argentina and Peru (OR 1.21 per +10-year of age, 95%CI:1.02-1.45; OR 1.20, 95%CI:1.02-1.43; respectively), but not in CSA (OR 1.07, 95%CI:0.94-1.21). Higher education was associated with decreased risk for LHI in Chile (OR 0.92 per +1-year of education, 95%CI:0.87-0.98) (similar trends in Mexico, Peru, and CSA). LHI with date of HIV-diagnosis available, 55% were LT and 45% LP.LHI was highly prevalent in CCASAnet sites, mostly due to LT; the main risk factors associated were being male and older age. Earlier HIV-diagnosis and earlier treatment initiation are needed to maximize benefits from HAART in the region.
- Published
- 2011
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.